{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:14:29Z","timestamp":1790255669077,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Semant"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A vaccine is a processed material that if administered, is able to stimulate an adaptive immune response to prevent or ameliorate a disease. A vaccination process may protect the host against subsequent exposure to an infectious agent and result in reduced disease or total prevention of the disease. Vaccine formulation and administration methods may affect vaccine safety and efficacy significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this report, the detailed classification and definitions of vaccine components and vaccine administration processes are represented using OWL within the framework of the Vaccine Ontology (VO). Different use cases demonstrate how different vaccine formulations and routes of vaccine administration affect the protection efficacy, general immune responses, and adverse events following vaccination. For example, vaccinations of mice with\n                      <jats:italic>Brucella abortus<\/jats:italic>\n                      vaccine strain RB51 using intraperitoneal or intranasal administration resulted in different protection levels. As shown in the vaccine adverse event data provided by US FDA, live attenuated and nonliving vaccines are usually administered in different routes and have different local and systematic adverse effect manifestations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vaccine formulation and administration route can independently or collaboratively affect host response outcomes (positive protective immunity or adverse events) after vaccination. Ontological representation of different vaccine and vaccination factors in these two areas allows better understanding and analysis of the causal effects between different factors and immune responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/2041-1480-3-17","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T12:15:14Z","timestamp":1356005714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses"],"prefix":"10.1186","volume":"3","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"123_CR1","volume-title":"The 1st International Conference on Biomedical Ontology (ICBO 2009)","author":"Y He","year":"2009","unstructured":"He Y, Cowell LG, Diehl AD, Mobley H, Peters B, Ruttenberg A, Scheuermann R, Brinkman RR, Courtot M, Mungall C: VO: Vaccine Ontology. The 1st International Conference on Biomedical Ontology (ICBO 2009). 2009, Buffalo, NY, USA: Nature Precedings, [http:\/\/precedings.nature.com\/documents\/3552\/version\/1]"},{"key":"123_CR2","first-page":"89","volume-title":"IFOMIS reports","author":"P Grenon","year":"2003","unstructured":"Grenon P: Spatio-temporality in Basic Formal Ontology. IFOMIS reports. Edited by: Grenon P. 2003, Leipzig: Institute for Formal Ontology and Medical Information Science at the Faculty of Medicine of the University, 89-"},{"issue":"5","key":"123_CR3","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/gb-2005-6-5-r46","volume":"6","author":"B Smith","year":"2005","unstructured":"Smith B, Ceusters W, Klagges B, Kohler J, Kumar A, Lomax J, Mungall C, Neuhaus F, Rector AL, Rosse C: Relations in biomedical ontologies. Genome Biol. 2005, 6 (5): R46-10.1186\/gb-2005-6-5-r46.","journal-title":"Genome Biol"},{"issue":"Database issue","key":"123_CR4","doi-asserted-by":"publisher","first-page":"D249","DOI":"10.1093\/nar\/gkp886","volume":"38","author":"P de Matos","year":"2010","unstructured":"de Matos P, Alcantara R, Dekker A, Ennis M, Hastings J, Haug K, Spiteri I, Turner S, Steinbeck C: Chemical Entities of Biological Interest: an update. Nucleic Acids Res. 2010, 38 (Database issue): D249-D254.","journal-title":"Nucleic Acids Res"},{"issue":"Suppl 21","key":"123_CR5","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1186\/2041-1480-1-S1-S7","volume":"21","author":"RR Brinkman","year":"2010","unstructured":"Brinkman RR, Courtot M, Derom D, Fostel J, He Y, Lord P, Malone J, Parkinson H, Peters B, Rocca-Serra P: Modeling biomedical experimental processes with OBI. Journal of Biomedical Semantics. 2010, 21 (Suppl 21): S7: 10.1186\/2041-1480-1-S1-S7.","journal-title":"Journal of Biomedical Semantics"},{"key":"123_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/978-1-4419-1327-2_19","volume-title":"Infectious Disease Informatics","author":"LG Cowell","year":"2010","unstructured":"Cowell LG, Smith B: Infectious Disease Ontology. Infectious Disease Informatics. Edited by: Sintchenko V. 2010, New York Dordrecht Heidelberg London: Springer, 373-395."},{"key":"123_CR7","volume-title":"Vaccines","author":"SA Plotkin","year":"2008","unstructured":"Plotkin SA, Orenstein WA, Offit PA: Vaccines. 2008, Philadelphia, PA: Saunder Elsevier, 5","edition":"5"},{"key":"123_CR8","doi-asserted-by":"publisher","first-page":"831486","DOI":"10.1155\/2012\/831486","volume":"2012","author":"S Sayers","year":"2012","unstructured":"Sayers S, Ulysse G, Xiang Z, He Y: Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development. J Biomed Biotechnol. 2012, 2012: 831486-[http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22505817]","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"123_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2004.12.020","volume":"104","author":"I Scholl","year":"2005","unstructured":"Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E: Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release. 2005, 104 (1): 1-27. 10.1016\/j.jconrel.2004.12.020.","journal-title":"J Control Release"},{"issue":"4","key":"123_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","volume":"33","author":"MA Liu","year":"2010","unstructured":"Liu MA: Immunologic basis of vaccine vectors. Immunity. 2010, 33 (4): 504-515. 10.1016\/j.immuni.2010.10.004.","journal-title":"Immunity"},{"issue":"Suppl 1","key":"123_CR11","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/2041-1480-1-S1-S7","volume":"1","author":"RR Brinkman","year":"2010","unstructured":"Brinkman RR, Courtot M, Derom D, Fostel JM, He Y, Lord P, Malone J, Parkinson H, Peters B, Rocca-Serra P: Modeling biomedical experimental processes with OBI. J Biomed Semantics. 2010, 1 (Suppl 1): S7-10.1186\/2041-1480-1-S1-S7.","journal-title":"J Biomed Semantics"},{"key":"123_CR12","first-page":"3","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"W Atkinson","year":"2011","unstructured":"Atkinson W, Wolfe C, Hamborsky J: Epidemiology and prevention of vaccine-preventable diseases. 2011, Atlanta: Dept. of Health & Human Services, Public Health Service, 3-4."},{"issue":"Suppl 4","key":"123_CR13","doi-asserted-by":"publisher","first-page":"D40","DOI":"10.1016\/j.vaccine.2009.08.058","volume":"27","author":"TA Ficht","year":"2009","unstructured":"Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC: Brucellosis: the case for live, attenuated vaccines. Vaccine. 2009, 27 (Suppl 4): D40-D43.","journal-title":"Vaccine"},{"issue":"8","key":"123_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nm1276","volume":"11","author":"DG Brockstedt","year":"2005","unstructured":"Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G: Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005, 11 (8): 853-860. 10.1038\/nm1276.","journal-title":"Nat Med"},{"issue":"3\u20134","key":"123_CR15","first-page":"103","volume":"125","author":"P van Gelder","year":"2012","unstructured":"van Gelder P, Makoschey B: Production of viral vaccines for veterinary use. Berl Munch Tierarztl Wochenschr. 2012, 125 (3\u20134): 103-109.","journal-title":"Berl Munch Tierarztl Wochenschr"},{"issue":"2","key":"123_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0378-1135(91)90091-S","volume":"28","author":"GG Schurig","year":"1991","unstructured":"Schurig GG, Roop RM, Bagchi T, Boyle S, Buhrman D, Sriranganathan N: Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol. 1991, 28 (2): 171-188. 10.1016\/0378-1135(91)90091-S.","journal-title":"Vet Microbiol"},{"issue":"11","key":"123_CR17","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1128\/iai.62.11.4990-4996.1994","volume":"62","author":"J de Bagues MP","year":"1994","unstructured":"de Bagues MP J, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ: Vaccination with Brucella abortus rough mutant RB51 protects BALB\/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis. Infect Immun. 1994, 62 (11): 4990-4996.","journal-title":"Infect Immun"},{"issue":"6","key":"123_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/infdis\/jir436","volume":"204","author":"DF Hoft","year":"2011","unstructured":"Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB: Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011, 204 (6): 845-853. 10.1093\/infdis\/jir436.","journal-title":"J Infect Dis"},{"issue":"12","key":"123_CR19","first-page":"1429","volume":"12","author":"N Sanakkayala","year":"2005","unstructured":"Sanakkayala N, Sokolovska A, Gulani J, Hogenesch H, Sriranganathan N, Boyle SM, Schurig GG, Vemulapalli R: Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. Clin Diagn Lab Immunol. 2005, 12 (12): 1429-1436.","journal-title":"Clin Diagn Lab Immunol"},{"key":"123_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bmb\/ldh021","volume":"70","author":"A Finn","year":"2004","unstructured":"Finn A: Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull. 2004, 70: 1-14. 10.1093\/bmb\/ldh021.","journal-title":"Br Med Bull"},{"issue":"4","key":"123_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1203\/00006450-199210000-00002","volume":"32","author":"RZ Dintzis","year":"1992","unstructured":"Dintzis RZ: Rational design of conjugate vaccines. Pediatr Res. 1992, 32 (4): 376-385. 10.1203\/00006450-199210000-00002.","journal-title":"Pediatr Res"},{"issue":"1","key":"123_CR22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7883\/yoken.63.8","volume":"63","author":"S Tamura","year":"2010","unstructured":"Tamura S, Hasegawa H, Kurata T: Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis. 2010, 63 (1): 8-15.","journal-title":"Jpn J Infect Dis"},{"issue":"5","key":"123_CR23","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1128\/IAI.70.5.2535-2543.2002","volume":"70","author":"Y He","year":"2002","unstructured":"He Y, Vemulapalli R, Schurig GG: Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect Immun. 2002, 70 (5): 2535-2543. 10.1128\/IAI.70.5.2535-2543.2002.","journal-title":"Infect Immun"},{"issue":"1\u20134","key":"123_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0378-1135(02)00255-9","volume":"90","author":"GG Schurig","year":"2002","unstructured":"Schurig GG, Sriranganathan N, Corbel MJ: Brucellosis vaccines: past, present and future. Vet Microbiol. 2002, 90 (1\u20134): 479-496.","journal-title":"Vet Microbiol"},{"issue":"8","key":"123_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1863-2378.2007.01063.x","volume":"54","author":"SC Olsen","year":"2007","unstructured":"Olsen SC, Waters WR, Stoffregen WS: An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses Public Health. 2007, 54 (8): 281-285. 10.1111\/j.1863-2378.2007.01063.x.","journal-title":"Zoonoses Public Health"},{"issue":"15","key":"123_CR26","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1016\/j.vaccine.2011.01.090","volume":"29","author":"N Surendran","year":"2011","unstructured":"Surendran N, Sriranganathan N, Lawler H, Boyle SM, Hiltbold EM, Heid B, Zimmerman K, Witonsky SG: Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB\/c mice. Vaccine. 2011, 29 (15): 2749-2755. 10.1016\/j.vaccine.2011.01.090.","journal-title":"Vaccine"},{"issue":"1","key":"123_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/erv.10.147","volume":"10","author":"B Cooper","year":"2011","unstructured":"Cooper B, DeTora L, Stoddard J: Menveo(R)): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011, 10 (1): 21-33. 10.1586\/erv.10.147.","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"123_CR28","doi-asserted-by":"publisher","first-page":"e49941","DOI":"10.1371\/journal.pone.0049941","volume":"7","author":"S Sarntivijai","year":"2012","unstructured":"Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y: Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS ONE. 2012, 7 (11): e49941-10.1371\/journal.pone.0049941.","journal-title":"PLoS ONE"},{"issue":"11","key":"123_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/nbt1346","volume":"25","author":"B Smith","year":"2007","unstructured":"Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, Goldberg LJ, Eilbeck K, Ireland A, Mungall CJ: The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol. 2007, 25 (11): 1251-1255. 10.1038\/nbt1346.","journal-title":"Nat Biotechnol"},{"key":"123_CR30","volume-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbook","author":"CDC","year":"2011","unstructured":"CDC: Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbook. 2011, Centers for Disease Control and Prevention, [http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/index.html]12","edition":"12"},{"issue":"Database issue","key":"123_CR31","first-page":"D923","volume":"36","author":"Z Xiang","year":"2008","unstructured":"Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y, Olenzek EA, Zhao B: VIOLIN: vaccine investigation and online information network. Nucleic Acids Res. 2008, 36 (Database issue): D923-928.","journal-title":"Nucleic Acids Res"},{"key":"123_CR32","unstructured":"Approved Vaccine Products by USA FDA. [http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/]"}],"container-title":["Journal of Biomedical Semantics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2041-1480-3-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/2041-1480-3-17","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2041-1480-3-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:11:25Z","timestamp":1790043085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/2041-1480-3-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,12]]}},"alternative-id":["123"],"URL":"https:\/\/doi.org\/10.1186\/2041-1480-3-17","relation":{},"ISSN":["2041-1480"],"issn-type":[{"value":"2041-1480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]},"assertion":[{"value":"22 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"17"}}